Vivistim System
Mobia Medical, Inc. · Decision date Sep 16, 2026
What did the FDA decide?
The FDA recorded decision OK30 on 2026-09-16 for P210007/S015, a 30-Day Notice supplement to the Vivistim® System held by Mobia Medical, Inc. The supplement reason is listed as a process change involving manufacturer, sterilizer, packager or supplier. The device category is an implanted autonomic nerve stimulator for stroke rehabilitation, with product code QPY and Physical Medicine as the specialty.
The recorded change concerns one component: Mobia Medical replaced the supplier of the Lead Connector Boot used in the Implantable Lead of the Vivistim Paired VNS System, moving from Trelleborg to ProMed. This notice covers that supplier substitution, not a new approval of the full system. The source does not include supporting documents, review detail, or any clinical or performance findings, so the basis for OK30 and any effect on the finished lead remain unknown.
FDA approval order statement
Mobia Medical has replaced their supplier for the Lead Connector Boot component of the Implantable Lead of the Vivistim Paired VNS System, transitioning from Trelleborg to ProMed.
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Physical Medicine
- Decision date
- Sep 16, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P210007/S015
- Regulatory pathway
- PMA supplement
- Applicant
- Mobia Medical, Inc.
- Product code
- QPY
- Decision code
- OK30
- Decision date
- Sep 16, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Stimulator, autonomic nerve, implanted for stroke rehabilitation.
- Applicant
- Mobia Medical, Inc.
- Product code
- QPY
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P210007. Subsequent supplements may change the device or its indications.
FDA decision timeline
P210007 · Original PMA
Vivistim System
P210007/S015 received
Application receipt date recorded by FDA.
P210007/S015 · FDA decision
30-Day Notice
Timeline entries are records held by MedtechLedger for P210007. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P210007
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Vivistim SystemP210007 | Mobia Medical, Inc. | PMA approval | Aug 27, 2021 | FDA |
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Mobia Medical, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 2802 Flintrock Trace, Suite 226, Austin, TX, 78738
Sources and methodology
- Original FDA record: P210007/S015
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records